The Food and Drug Administration  has added nine drug products to the list of essential medicines that are exempted from ...

The drug was approved in Europe in 2018, with AZ predicting blockbuster sales, but has so far proved to be a relatively slow grower with sales of $122 million in the third quarter of 2021, albeit ...

AT-II-receptor antagonists include losartan, valsartan, irbesartan, candesartan, eprosartan, telmisartan, and tasosartan. Several clinical trials have demonstrated that AT-II-receptor antagonists ...

When irbesartan therapy is discontinued, the dosage does not need to be tapered, regardless of the daily dose administered, because abrupt withdrawal of the drug is not associated with an increase ...